First Trust Advisors LP Purchases New Shares in ARS Pharmaceuticals, Inc. $SPRY

First Trust Advisors LP acquired a new stake in shares of ARS Pharmaceuticals, Inc. (NASDAQ:SPRY) during the first quarter, according to its most recent Form 13F filing with the SEC. The fund acquired 422,038 shares of the company’s stock, valued at approximately $3,389,000. First Trust Advisors LP owned 0.43% of ARS Pharmaceuticals at the end of the most recent quarter.

Several other institutional investors and hedge funds have also recently modified their holdings of SPRY. Torren Management LLC bought a new stake in ARS Pharmaceuticals during the 4th quarter valued at approximately $32,000. Mirae Asset Global Investments Co. Ltd. raised its position in shares of ARS Pharmaceuticals by 25.7% in the 4th quarter. Mirae Asset Global Investments Co. Ltd. now owns 4,803 shares of the company’s stock worth $56,000 after acquiring an additional 982 shares in the last quarter. Bessemer Group Inc. lifted its stake in shares of ARS Pharmaceuticals by 3,102.1% in the 1st quarter. Bessemer Group Inc. now owns 7,525 shares of the company’s stock valued at $61,000 after purchasing an additional 7,290 shares during the period. Osterweis Capital Management Inc. purchased a new position in shares of ARS Pharmaceuticals in the 4th quarter valued at approximately $65,000. Finally, Russell Investments Group Ltd. boosted its position in shares of ARS Pharmaceuticals by 197.5% during the third quarter. Russell Investments Group Ltd. now owns 6,668 shares of the company’s stock valued at $67,000 after purchasing an additional 4,427 shares in the last quarter. 68.16% of the stock is owned by hedge funds and other institutional investors.

ARS Pharmaceuticals Trading Up 3.5%

NASDAQ SPRY opened at $5.55 on Friday. ARS Pharmaceuticals, Inc. has a 12 month low of $4.91 and a 12 month high of $18.00. The stock has a market cap of $551.13 million, a P/E ratio of -2.76 and a beta of 0.98. The stock’s fifty day moving average price is $7.94 and its 200-day moving average price is $8.48. The company has a current ratio of 4.94, a quick ratio of 4.77 and a debt-to-equity ratio of 2.79.

ARS Pharmaceuticals (NASDAQ:SPRY) last posted its quarterly earnings results on Friday, May 15th. The company reported ($0.61) earnings per share (EPS) for the quarter, missing the consensus estimate of ($0.53) by ($0.08). The company had revenue of $22.68 million during the quarter, compared to analysts’ expectations of $22.20 million. ARS Pharmaceuticals had a negative return on equity of 153.61% and a negative net margin of 200.00%. As a group, equities analysts forecast that ARS Pharmaceuticals, Inc. will post -1.95 EPS for the current fiscal year.

Insider Activity at ARS Pharmaceuticals

In other news, insider Eric Karas sold 25,000 shares of the company’s stock in a transaction that occurred on Friday, June 12th. The shares were sold at an average price of $10.00, for a total value of $250,000.00. Following the transaction, the insider owned 12,176 shares in the company, valued at approximately $121,760. This represents a 67.25% decrease in their ownership of the stock. The sale was disclosed in a filing with the SEC, which is accessible through this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, insider Alexander A. Fitzpatrick sold 3,355 shares of the business’s stock in a transaction that occurred on Friday, June 12th. The stock was sold at an average price of $10.00, for a total transaction of $33,550.00. Following the completion of the transaction, the insider owned 90,910 shares of the company’s stock, valued at approximately $909,100. The trade was a 3.56% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Corporate insiders own 33.80% of the company’s stock.

Analysts Set New Price Targets

A number of analysts have recently commented on the stock. Wall Street Zen upgraded shares of ARS Pharmaceuticals from a “strong sell” rating to a “sell” rating in a report on Saturday, May 16th. Northland Securities assumed coverage on shares of ARS Pharmaceuticals in a research note on Thursday, April 9th. They issued an “outperform” rating and a $25.00 price target for the company. Weiss Ratings raised shares of ARS Pharmaceuticals from a “sell (e+)” rating to a “sell (d-)” rating in a research report on Monday, June 1st. Leerink Partners dropped their price objective on shares of ARS Pharmaceuticals from $25.00 to $24.00 and set an “outperform” rating on the stock in a research note on Thursday, June 25th. Finally, Cantor Fitzgerald upped their price objective on shares of ARS Pharmaceuticals from $12.00 to $30.00 and gave the stock an “overweight” rating in a report on Thursday, May 28th. Four research analysts have rated the stock with a Buy rating, one has assigned a Hold rating and one has given a Sell rating to the stock. According to data from MarketBeat, the company presently has an average rating of “Moderate Buy” and an average target price of $28.20.

ARS Pharmaceuticals News Roundup

Here are the key news stories impacting ARS Pharmaceuticals this week:

• Negative Sentiment: Several law firms announced or promoted a securities class action covering investors who purchased SPRY shares between March 9 and June 24, 2026. The complaints allege ARS Pharmaceuticals made misleading statements or failed to disclose risks related to the timing of expanded CVS Caremark insurance coverage for neffy. SPRY Investors Have Opportunity to Lead ARS Pharmaceuticals, Inc. Securities Fraud Lawsuit
• Negative Sentiment: The allegations center on a missed July 1, 2026 CVS Caremark formulary-coverage timeline, reportedly delayed until January 2027. Investors and analysts viewed the delay as a negative surprise because broader coverage could be important to neffy’s adoption and revenue growth. A lead-plaintiff deadline of October 5, 2026 has been announced. SPRY Investor Alert
• Neutral Sentiment: ARS Pharmaceuticals is expected to report quarterly results Thursday. Investors will likely focus on neffy sales, commercial progress, cash resources and management’s explanation of the CVS Caremark timing. ARS Pharmaceuticals Expected to Post Earnings

ARS Pharmaceuticals Profile

ARS Pharmaceuticals, Inc, a biopharmaceutical company, develops treatments for severe allergic reactions. The company is developing neffy, a needle-free and low-dose intranasal epinephrine nasal spray for the emergency treatment of Type I allergic reactions, including anaphylaxis. It serves healthcare professionals, patients, and caregivers. ARS Pharmaceuticals, Inc was founded in 2015 and is headquartered in San Diego, California.